Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes
September 07 2016 - 09:24PM
Business Wire
Thermo Fisher Scientific Inc. (NYSE: TMO) announced today that
it has priced an offering of €1.0 billion aggregate principal
amount of its 0.750% senior notes due 2024 and €600 million
aggregate principal amount of its 1.375% senior notes due 2028 at
the issue prices of 99.122% of the principal amount and 99.748% of
the principal amount, respectively.
The issuance of the notes is expected to close on or about
September 12, 2016, subject to customary closing conditions. The
notes will pay interest on an annual basis.
Thermo Fisher intends to use the net proceeds of the offering to
finance a portion of the estimated $4.2 billion purchase price for
its acquisition of FEI Company and to pay certain associated costs.
The FEI acquisition is expected to close by December 31, 2016,
subject to the satisfaction of customary closing conditions,
including applicable regulatory approvals.
The joint book-running managers for the offering are J.P. Morgan
Securities plc, Barclays Bank PLC, Mizuho International plc and
Morgan Stanley & Co. International plc.
The offering is being made pursuant to an effective registration
statement on Form S-3, as amended by the post-effective amendment
thereto (including a prospectus), filed with the U.S. Securities
and Exchange Commission (the “SEC”). Prospective investors should
read the prospectus forming a part of that registration statement
and the prospectus supplement related to the offering and the other
documents that the company has filed with the SEC for more complete
information about the company and this offering. These documents
are available at no charge by visiting EDGAR on the SEC website at
www.sec.gov. Alternatively, Thermo Fisher, the underwriters or any
dealer participating in this offering will arrange to send you the
prospectus if you request it by calling J.P. Morgan Securities plc
collect at +44 207-134-2468; by calling Barclays Bank PLC toll-free
at 1-888-603-5847; by calling Mizuho International plc toll-free at
+44 207-090-6929; or by calling Morgan Stanley & Co.
International plc toll-free at 1-866-718-1649.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy the notes, nor shall there be any
offer, solicitation or sale of the notes in any jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
the registration or qualification under the securities laws of any
such jurisdiction.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including, but not limited to, statements about the company’s
intended use of proceeds. These statements involve a number of
risks and uncertainties that could cause actual results to differ
materially from currently anticipated results, including risks and
uncertainties relating to capital markets conditions and completion
of the offering. Additional important factors and information
regarding Thermo Fisher’s business that could cause actual results
to differ materially from those indicated by such forward-looking
statements are set forth in the prospectus and prospectus
supplement dated September 7, 2016 related to the offering, which
is on file with the SEC and available in the “Investors” section of
our website under the heading “SEC Filings,” and the documents
incorporated by reference into the prospectus and prospectus
supplement. While we may elect to update forward-looking statements
at some point in the future, we specifically disclaim any
obligation to do so, even if circumstances change and, therefore,
you should not rely on these forward-looking statements as
representing our views as of any date subsequent to today.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160907006925/en/
Thermo Fisher Scientific Inc.Media Contact Information:Ron
O’Brien, 781-622-1242ron.obrien@thermofisher.comorInvestor Contact
Information:Ken Apicerno,
781-622-1294ken.apicerno@thermofisher.com
Thermo Fisher Scientific (NYSE:TMO)
Historical Stock Chart
From Feb 2024 to Mar 2024
Thermo Fisher Scientific (NYSE:TMO)
Historical Stock Chart
From Mar 2023 to Mar 2024